Drugs / HPV 6/11 bivalent vaccine
HPV 6/11 bivalent vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02405520 | Mar 2015 → Jun 2019 | anogenital human papillomavirus infection | Jun Zhang | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00710593 Comparator | Feb 2008 → Feb 2011 | HIV infectious disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV 6/11 bivalent vaccine | “Participants would intramuscularly receive low dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.” NCT02405520 ↗ |
| Known as | HPV-6, -11, -16, -18 vaccine | “Immunogenicity, Safety, Tolerability, and Behavioral Consequences of an HPV-6, -11, -16, -18 Vaccine in HIV-Infected Young Women” NCT00710593 ↗ |
| Known as | HPV-6/11 vaccine | “participants were randomly assigned to receive either 30, 60, or 90 μg of the HPV-6/11 vaccine (n = 41/40/40) or the parallel placebo vaccine” PMID 35834812 ↗ Jul 2022 |
| Known as | novel recombinant HPV type 6/11 bivalent vaccine | “This phase I clinical study was designed to evaluate the safety and immunogenicity of the novel recombinant HPV type 6/11 bivalent vaccine, manufactured by Xiamen Innovax...” NCT02405520 ↗ |
| Known as | Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine | “A Phase I Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent...” NCT02405520 ↗ |
| Modality | Vaccine | “3-dose quadrivalent human papillomavirus (HPV) vaccine series” PMID 23667266 ↗ May 2013 |
| Route | Intramuscular | “Participants would intramuscularly receive low dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.” NCT02405520 ↗ |